CXCL9 and neoplasm: When ctDNA detection was combined with the level of tumour mutational burden (TMB) and a tumour-derived interferon signature (including HLA-DRA, CXCL9/10/11, GZMA, PRF1, CCR5, IFNG, IDO1 and STAT1), the predictive value of the combined score was enhanced [79].